Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Assessment Of Ferroptosis As A Promising Candidate For Metastatic Uveal Melanoma Treatment And Prognostication.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Assessment Of Ferroptosis As A Promising Candidate For Metastatic Uveal Melanoma Treatment And Prognostication.

    • Related Experiment Video

    Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
    09:52

    Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

    Published on: January 25, 2015

    13.4K

    Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication.

    Ellie Swords1,2, Breandán N Kennedy1,2, Valentina Tonelotto1,2

    • 1UCD Conway Institute, University College Dublin, Dublin, Ireland.

    Frontiers in Pharmacology
    |October 16, 2024

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Uveal melanoma (UM) is a common eye cancer. New research explores ferroptosis, a cell death pathway, as a potential treatment and prognostic tool for metastatic UM (mUM).

    Keywords:
    ferroptosismetastasisprognosistreatmentuveal melanoma

    More Related Videos

    Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
    05:46

    Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

    Published on: December 2, 2022

    1.7K
    Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
    04:01

    Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

    Published on: March 15, 2024

    880

    Related Experiment Videos

    Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
    09:52

    Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

    Published on: January 25, 2015

    13.4K
    Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
    05:46

    Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

    Published on: December 2, 2022

    1.7K
    Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
    04:01

    Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

    Published on: March 15, 2024

    880

    Area of Science:

    • Oncology
    • Cell Biology
    • Ophthalmology

    Background:

    • Uveal melanoma (UM) is the most frequent primary intraocular tumor in adults.
    • Current treatments for UM include local resection, radiation, and enucleation.
    • Approximately 50% of UM patients develop metastatic disease (mUM) within 5-7 years, with poor survival rates.

    Purpose of the Study:

    • To review the potential of ferroptosis as a novel therapeutic target and prognostic biomarker for uveal melanoma.
    • To highlight the urgent need for improved treatments and prognostic models for metastatic UM.

    Main Methods:

    • Review of existing scientific literature on uveal melanoma, metastasis, and ferroptosis.
    • Analysis of current treatment strategies and their limitations for mUM.
    • Exploration of gene expression signatures for prognostic modeling.

    Main Results:

    • Metastatic UM has a median survival of 3.6 months, with limited treatment options and efficacy.
    • Existing treatments for mUM offer only marginal survival benefits.
    • Gene expression signatures are being developed to improve prognostication and patient management.

    Conclusions:

    • Ferroptosis presents a promising avenue for novel treatment strategies in mUM.
    • Targeting ferroptosis could offer a new approach to managing this aggressive cancer.
    • Improved prognostic models are essential for better patient follow-up and treatment decisions.